ClinicalTrials.gov
public full text
Public Domain
Myeloperoxidase (MPO) Inhibitor A_Zeneca for Heart Failure With Preserved Ejection Fraction (HFpEF)
Researchers are studying the effect of a single dose of oral myeloperoxidase on heart failure versus placebo.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients#980481
- Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor Response#871286
- Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole#230493
- Randomized Placebo-controlled Trial of Inhaled iNO in Acute ST-segment Elevation MI Treated by Primary Angioplasty#1127094
- Evaluation of the Delivery of Optimized Supersaturated Oxygen Therapy to Treat Patients With an Acute Heart Attack#842024
Record · ID 1125124
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive